about
The Inflammatory Response in Psoriasis: a Comprehensive Review.Chronic skin inflammation leads to bone loss by IL-17-mediated inhibition of Wnt signaling in osteoblasts.Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis.The psoriasis-associated IL-17A induces and cooperates with IL-36 cytokines to control keratinocyte differentiation and function.Moderate to severe psoriasis treatment challenges through the era of biological drugs.Serum 25-hydroxyvitamin D levels in patients with skin diseases including psoriasis, infections, and atopic dermatitis.
P2860
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Secukinumab (AIN457) for the treatment of psoriasis.
@en
type
label
Secukinumab (AIN457) for the treatment of psoriasis.
@en
prefLabel
Secukinumab (AIN457) for the treatment of psoriasis.
@en
P2093
P2860
P1476
Secukinumab (AIN457) for the treatment of psoriasis.
@en
P2093
Anna López-Ferrer
Eva Vilarrasa
Lluís Puig
P2860
P304
P356
10.1586/1744666X.2015.1095092
P577
2015-10-01T00:00:00Z